Technology Platform
Simply decoding cancer’s complexity
Our panels enable any molecular lab to generate high-quality sequencing results to turn liquid and tissue biopsies into powerful genomic insights.
Our next-generation sequencing (NGS) platform combines proprietary chemistry, a streamlined workflow and powerful analytics to provide meaningful insights.
Proprietary chemistry
Anchored Multiplex PCR (AMP™) target enrichment chemistry at the core of our products
- Close
Quantitative NGS
Molecular barcodes (MBC) enable unique molecule identification for powerful statistical advantages.
Partner-agnostic fusion detection
Specialized adapter for open-ended amplification and robust novel fusion detection from RNA
Optimal capture
Uni-directional priming allows for optimal capture efficiency of short, degraded FFPE or ctDNA fragments.
High Sensitivity
Strand specificity and MBCs power industry-leading error correction for ultra-low allele frequency detection.
Streamlined workflow
Easy-to-use reagents are shipped in a convenient pre-packaged format
- Close
Fast library preparation
2.5 hours hands-on time with library prepared in 8-10 hours total.
Reproducible results
Regardless of expertise.
No master mixes
Test kits contain lyophilized reagents that reduce pipetting events and chance of human error.
Flexible to scale.
Test kits are provided in 8-strip tubes or 96-well plates.
Powerful analytics
Bioinformatics software allows for data control and provides easily understandable outputs
- Close
Confident results
Our Analysis leverages MBCs for advanced statistical support and outlier detection.
Tiered results interpretation and reporting
Simple in-line visualization for quick review or take a deep dive into the data. Fit to your lab needs. Provided as a virtual machine to install behind your firewall, or as a secure-cloud based instance.
Flexible
Robust API for LIMS and clinical interpretation integration.
Inherent technological advantages
RNA
DNA
Footnotes:
- Benyaed, R. et al. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clin Cancer Res 2019;25:4712–22.
- Qu, X. et al. Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN. 2020;243:11-18.
- Solomon, J et al. NTRK fusion detection across multiple assays and 33,997 cases- diagnostic implications and pitfalls. Modern Pathology. 2020(33);38–46.
- Afrin, S et al. Targeted Next-Generation Sequencing for Detecting MLL Gene Fusions in Leukemia. Mol Cancer Res; 16(2); 279–85.